NCT01494324Active, not recruiting
Examinations of Tissue From Ablated Malignant Liver Metastases as Predictors of Outcome
Source: ClinicalTrials.gov · Last updated 3 Nov 2026
Brief summary (registry, in English)
The purpose of this study is to see if the investigators can do some tests on tissue from the area of the ablation. The investigators want to know if a test can help predict whether the ablation worked. The treated tumor is normally evaluated with CT. The CT shows signs of treated tumor(s) in the area treated by ablation. However, cancer cells may begin to grow in or near the treated area. The CT scan cannot tell us if the cells are new cancer cells or if they are healthy liver cells that just look different because of the ablation. The test the investigators will study should be able to tell us the difference.
- Status (registry)
- Active, not recruiting
- Study type
- Interventional
- Enrollment
- 150 (actual)
- First submitted
- 13 Dec 2011
- Start date
- 27 Oct 2009
- Primary completion date
- Oct 2027
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Diseases
- Liver and biliary tract cancer
- NCT number
- NCT01494324
What you commit to
- Study type: Interventional
- Participants enrolled: 150
- From 27 Oct 2009 to the primary completion date, Oct 2027
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Patient with more than 3 tumors treated with any percutaneous ablation
Other illness
- Patients with more than 5 sites of extrahepatic disease (including nodes and pulmonary nodules)
- for patients on Coumadin general clinical guidelines for IR ablation will be followed \*\*This will not be considered an exclusion criteria when IRE or Microwave is used.
- This will not be considered exclusion when IRE is used
Lab values
- INR \> 1.5 that cannot be corrected with fresh frozen Plasma\*
- Platelet count of \<50,000 that cannot be corrected with transfusion.
Other
- Patients \< 18
- Less than 5 mm distance of the tumor margin from a major vessel \>7mm in diameter)\*\*
- Less than 5 mm distance to a structure (GI or biliary tract), that cannot be protected from\*\*
- the ablation injury with technical modifications such as hydro or air dissection.
Who the study is looking for
- Patients with diagnosed with secondary hepatic malignancy;
- Patients with confined liver disease or stable limited extrahepatic disease;
- Lesions of 5cm or less in maximum diameter;
- Patients who are not surgical candidates or refuse to undergo surgery and choose any percutaneous ablation as an alternative treatment option.
- INR\<1.5 \*for patients on Coumadin general clinical guidelines for IR ablation will be followed.
- Platelet count \> or = to 50,000
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Memorial Sloan-Kettering Cancer Center Coordinator of this site? Confirm its status | New York | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.